Novartis’ Kisqali (ribociclib) (as a Combination Therapy) Receives CHMP’s Expanded Label Recommendation for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

 Novartis’ Kisqali (ribociclib) (as a Combination Therapy) Receives CHMP’s Expanded Label Recommendation for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Novartis’ Kisqali (ribociclib) (as a Combination Therapy) Receives CHMP’s Expanded Label Recommendation for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Shots:

  • The combination therapy recommendation of Kisqali plus endocrine therapy is based on results of P-III MONALEESA-7 and MONALEESA-3 trials assessing Kisqali vs endocrine therapy alone in women with HR+/HER2- Locally Advanced or Metastatic Breast Cancer
  • P-III MONALEESA-7 and MONALEESA-3 study results: mPFS (27.5 mos., 20.5 mos. vs 13.8 mos., 12.8 mos.) as 1L or 2L treatment, no safety issues, with improvement in 8 weeks
  • Kisqali is a cyclin-dependent kinase inhibitor of two proteins, i.e. cyclin-dependent kinase 4 and 6 (CDK4/6) indicated for the treatment of HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Click here to read full press release/ article | Ref: Novartis| Image:  Fortune

 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post